83697-75-0

Upstream product

• 156-43-4 4-Ethoxyaniline 
• 532-55-8 Benzoyl isothiocyanate 
• 14002-51-8 4-biphenyl-carboxylic acid chloride 
• 98-88-4 benzoyl chloride 

Downstream Products

• 19345-26-7 2-benzoylimino-3-(4-ethoxy-phenyl)-4-methyl-thiazolidin-4-ol 
• 131329-62-9 (N-(4-ethoxyphenyl)-N'-benzoylthiocarbamide)(H₂O)iron(III) succinimide 
• 472981-27-4 2-(4-ethoxyphenylamino)-4-(2-methyl-imidazo[1,2-a]pyrimidin-3-yl)thiazole monohydrobromide 
• 19345-28-9 2-benzoylimino-3-(4-ethoxy-phenyl)-4-phenyl-thiazolidin-4-ol 
• 880-29-5 1-(4-ethoxyphenyl)thiourea 
• 131329-58-3 (N-(4-ethoxyphenyl)-N'-benzoylthiocarbamide)(H₂O)iron(III) phthalimide 
• 19345-31-4 N-[3-(4-ethoxy-phenyl)-4-methyl-3H-thiazol-2-ylidene]-benzamide 
• 19353-45-8 3-(4-ethoxy-phenyl)-4-phenyl-3H-thiazol-2-ylideneamine 
• 19353-44-7 3-(4-ethoxy-phenyl)-4-methyl-3H-thiazol-2-ylideneamine 

Relevant academic research and scientific papers

Antitubercular activities of the novel synthesized 1,2,4-triazole derivatives

1,2,4-Triazoles exert antimycobacterial activity by inhibiting the cell wall biosynthesis. In an attempt to developing lead compounds exhibiting antitubercular activities, a series of 1,2,4-triazole derivatives were synthesized by introducing various substitutes into a scaffold and the antitubercular activity was evaluated. The most potent compounds 3e and 8d showed their minimum inhibitory concentrations against Mycobacterium tuberculosis as 12.5 ??M. The results indicate that those compounds can be considered as leads for further development of new 1,2,4-triazole type candidates with high antitubercular activities.

Design and synthesis of N-Aryl isothioureas as a novel class of gastric H+/K+-ATPase inhibitors

To find new H+/K+-ATPase inhibitors for the treatment of peptic ulcer disease, a series of novel N-aryl isothiourea derivatives were synthesized and their structures were identified by 1H NMR and GC-MS. The effects of these compounds on inhibiting gastric acid secretion were evaluated by the guinea pig stomach mucous membrane study with pantoprazole magnesium as a positive control. The results showed that, of the 37 N-aryl isothiourea compounds synthesized, 20 compounds have comparable or stronger gastric acid inhibitory activities than that of pantoprazole magnesium. The quantitative structure-activity relationships (QSARs) of the N-aryl isothiourea compounds were also studied by comparative molecular field analysis (CoMFA) computation, and the model structure that was supposed to give more powerful bioactivities was finally predicted. A series of novel N-aryl isothiourea derivatives were synthesized and evaluated for their effects of inhibiting gastric acid secretion using the guinea pig stomach mucous membrane study with pantoprazole magnesium as a positive control. Compounds 2c, 2e, and 2k have higher bioactivity. The quantitative structure-activity relationships also defined these structural requirements.

HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS

Novel compounds having a fused bicyclic heteroaromatic ring system substituted with a thiazole ring are disclosed. The compounds inhibit growth of a variety of types of cancer cells, and are thus useful for treating cancer. Efficacy of these compounds is demonstrated with a system for monitoring cell growth/migration, which shows they are potent inhibitors of growth and/or migration of cancer cells. In addition, compounds of the invention were shown to stop growth of tumors in vivo, and to reduce the size of tumors in vivo. Compositions comprising these compounds, and methods to use these compounds and compositions for treatment of cancers, are disclosed.

HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS

Novel compounds having a fused bicyclic heteroaromatic ring system substituted with a heteroaryl five-membered ring are disclosed. The compounds inhibit growth of a variety of types of cancer cells, and are thus useful for treating cancer. Efficacy of these compounds is demonstrated with a system for monitoring cell growth/migration, which shows they are potent inhibitors of growth and/or migration of cancer cells. In addition, compounds of the invention were shown to stop growth of tumors in vivo, and to reduce the size of tumors in vivo. Compositions comprising these compounds, and methods to use these compounds and compositions for treatment of cancers, are disclosed.

STUDIES ON THE MOESSBAUER SPECTRA OF SOME IRON(III) COMPLEXES WITH IMIDES AS PRIMARY AND SOME N-ARYL-N'-BENZOYLTHIOCARBAMIDES AS SECONDARY LIGANDS. EFFECT OF AMBIENT TEMPERATURE

Ten new mixed ligand complexes of iron(III) of the type , where Im = deprotonated phthalimide or succinimide and STC = some N-aryl-N'-benzoylthiocarbamide derivativesN-(2-chlorophenyl)-N'-benzoylthiocarbamide, N-(3-methoxyphenyl)-N'-be